Brief: 3D Medicines Updates On Arbitration Proceedings Against Sellas Life Sciences
27/07/2026 16:03
BRIEF-3D Medicines Updates On Arbitration Proceedings Against Sellas Life Sciences July 27 (Reuters) - 3D Medicines Inc 1244.HK:
ARBITRATION PROCEEDINGS AGAINST SELLAS LIFE SCIENCES- GROUP
SOLE ARBITRATOR DISMISSES ALL CLAIMS BY SELLAS AGAINST 3D MEDICINES
SELLAS ORDERED TO PAY 3D MEDICINES HK$8 MILLION IN ARBITRATION COSTS BY AUG 7, 2026
ARBITRATION DOES NOT AFFECT LICENCE AGREEMENT PERFORMANCE BETWEEN 3D MEDICINES AND SELLAS
Further company coverage: 1244.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3D Medicines
See all newsArbitrator Dismisses Company's Claims In Arbitration Against 3D Medicines On July 24, 2026 - SEC Filing
Brief: 3D Medicines Updates On Arbitration Proceedings Against Sellas Life Sciences
Brief: 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Brief: 3D Medicines Inc Says Zhang Jing Resigns As CFO
Brief: 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted